<DOC>
	<DOC>NCT01438892</DOC>
	<brief_summary>Several observational studies have evaluated the comparative treatment costs associated with each agent, particularly those within the anti-TNF class, but few have evaluated the impact of therapy compliance, persistence, treatment patterns on patient reported outcomes, healthcare utilization and costs, using a provider database. This study is designed to fill in this information gap.</brief_summary>
	<brief_title>Impact Of RA Therapy Compliance On Patient-Reported Outcomes</brief_title>
	<detailed_description>Cohort observational</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Adults with moderate to severe RA who are currently using a DMARD Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), NonDisease modifying antirheumatic disease (nonDMARD) use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>therapy compliance</keyword>
</DOC>